Cytokines, stress, and depressive illness

Brain, Behavior, and Immunity

Volumn 16, Issue 5, 2002, Pages 513-524

  Anisman, H ^a,b   Merali, Z ^b,c  

^a CARLETON UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anxiety; Cytokine; Depression; Interleukin 1; Interleukin 2; Neuroendocrine; Stress

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GAMMA INTERFERON; GLYCOPROTEIN; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SERINE PROTEINASE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANHEDONIA; BEHAVIOR; BRAIN REGION; BYSTANDER EFFECT; CANCER; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; CONFERENCE PAPER; CORRELATION ANALYSIS; CORTICOTROPIN RELEASE; CYTOKINE PRODUCTION; DEPRESSION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HUMAN; ILLNESS BEHAVIOR; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; NATURAL KILLER CELL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; STRESS; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; MENTAL STRESS; REVIEW;

CYTOKINES; DEPRESSIVE DISORDER; HUMANS; STRESS, PSYCHOLOGICAL;

EID: 0036429079     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(02)00009-0     Document Type: Conference Paper

References (92)

1. Anisman, H., & Merali, Z. (1999). Anhedonic and anxiogenic effects of cytokine exposure. Adv. Exp. Med. Biol., 461, 199-233.
2. Anisman, H., Hayley, S., Staines, W., & Merali, Z. (2001). Cytokines, stress, and neuroehemical change: Immediate and proactive effects. In C. A. Shaw, & J. C. McEachern (Eds.), Towards a Theory of Neuroplasticity (pp. 301-320). Philadelphia: Psychology Press.
3. Anisman, H., Kokkinidis, L., & Merali, Z. (2002). Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. Brain, Behav. Immun., 16, 544-556.
4. Anisman, H., Merali, Z., & Kokkinidis, L. (1996). Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res., 731, 1-11.
5. Anisman, H., Ravindran, A. V., Griffiths, J., & Merali, Z. (1999a). Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry, 4, 182-188.
6. Anisman, H., Ravindran, A. V., Griffiths, J., & Merali, Z. (1999b). Interleukin-1β production in dysthymia before and after pharmacotherapy. Biol. Psychiatry, 46, 1649-1655.
7. Anisman, H., Zaharia, M. D., Meaney, M. J., & Merali, Z. (1998). Do early-life events permanently alter behavioral and hormonal responses to stressors? Int. J. Dev. Neurosci., 16, 149-164.
8. Anisman, H., Zalcman, S., & Zacharko, R. M. (1993). The impact of stressors on immune and central transmitter activity: Bidirectional communication. Rev. Neurosci., 4, 147-180.
9. Banks, W. A. (2001). Cytokines, CVOs, and the blood-brain barrier. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 483-497). New York: Academic Press.
10. Berk, M., Wadee, A. A., Kuschke, R. H., & O'Neill-Kerr, A. (1997). Acute phase proteins in major depression. J. Psychosom. Res., 43, 529-534.
11. Blalock, I. E. (1994). The syntax of immune-neuroendocrine communication. Immunol. Today, 15, 504-511.
12. Borowski, T., Kokkinidis, L., Merali, Z., & Anisman, H. (1998). Lipopolysaccharide, central in vivo amine alterations, and anhedonia. NeuroReport, 9, 3797-3802.
13. Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom. Med., 63, 376-386.
14. Capuron, L., Ravaud, A., & Dantzer, R. (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon α-2b therapy. J. Clin. Oncol., 18, 2143-2151.
15. Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F., & Cascinelli, N. (1992). Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur. J. Cancer, 29A, 1266-1269.
16. Cover, H., & Irwin, M. (1994). Immunity and depression: insomnia, retardation and reduction of natural killer cell activity. J. Behav. Med., 17, 217-223.
17. Dantzer, R., Bluthe, R. M., Aubert, A., Goodall, G., Bret-Dibat, J.-L., Kent, S., Goujon, E., Laye, S., Parnet, P., & Kelley, K. W. (1996). Cytokine actions on behavior. In N. J. Rothwell (Ed.), Cytokines and the nervous system (pp. 117-144). London: Landes.
18. Dantzer, R., Bluthe, R. M., Aubert, A., Goodall, G., Bret-Dibat, J.-L., Kent, S., Goujon, E., Laye, S., Pamet, P., & Kelley, K. W. (1999). Mechanisms of the behavioral effects of cytokines. Adv. Exp. Med. Biol., 461, 83-106.
19. Davis, M., Rainnie, D., & Cassell, M. (1994). Neuro-transmission in the rat amygdala related to fear and anxiety. Trends Neurosci., 17, 208-214.
20. Demitrack, M. A., Dale, J. K., Straus, S. E., Laue, L., Listwak, S. J., Kruesi, M. J. P., Chrousos, G. P., & Gold, P. W. (1991). Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab., 148, 337-344.
21. Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson, L., Seipp, L. A., Lotze, M. T., Chang, A. E., Rosenstein, D., & Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med., 107, 293-300.
22. Deutch, A. Y., & Roth, R. H. (1990). The determinants of stress-induced activation of the prefrontal cortical dopamine system. In H. B. M. Uylings, C. G. Van Eden, J. P. C. De Bruin, M. A. Corner, & M. G. P. Feenstra (Eds.), Progress in Brain Research (pp. 367-403). New York: Elsevier.
23. Dunn, A. J. (1995). Interactions between the nervous system and the immune system. In F. E. Bloom, & D. J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 719-731). New York: Raven Press.
24. Dunn, A. J. (2001). Effects of cytokines and infections on brain neurochemistry. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 649-666). New York: Academic Press.
25. Ericsson, A., Kovacs, K. J., & Sawchenko, P. E. (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J. Neurosci., 14, 89-91.
26. Frommberger, U. H., Bauer, J., Haselbauer, P., Fraulin, A., Riemann, D., & Berger, M. (1997). Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci., 247, 228-233.
27. Gold, P. W., Licinio, J., Wong, M. L., & Chrousos, G. P. (1995). Corticotropin releasing hormone in pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann. N.Y. Acad. Sci., 771, 716-729.
28. Griffiths, J., Ravindran, A. V., Merali, Z., & Anisman, H. (2000). Dysthymia: Neurochemical and behavioral perspectives. Mol. Psychiatry, 5, 242-261.
29. Griffiths, J., Ravindran, A. V., Merali, Z., & Anisman, H. (1996). Immune and behavioral correlates of typical and atypical depression. Soc. Neurosci. Abst., 22, 1350.
30. Hayley, S., Lacosta, S., Merali, Z., van Rooijen, N., & Anisman, H. (2001a). Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross-sensitization effects. Eur. J. Neurosci. 13, 1155-1165.
31. Hayley, S., Brebner, K., Merali, Z., & Anisman, H. (1999). Sensitization to the effects of tumor necrosis factor-α: Neuroendocrine, central monoamine, and behavioral variations. J. Neurosci., 19, 5654-5665.
32. Hayley, S., Staines, W. M., Merali, Z., & Anisman, H. (2001b). Time-dependent sensitization of corticotropin releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-α. Neuroscience, 106, 137-148.
33. Herbert, T. B., & Cohen, S. (1993). Stress and immunity in humans: A meta-analytic review. Psychosom. Med., 55, 364-379.
34. Irwin, M. (1999). Immune correlates of depression. Adv. Exp. Med. Biol., 461, 1-24.
35. Irwin, M. R., Smith, T. L., & Gillin, J. C. (1992). Electroencephalographic sleep and natural killer cell activity in depressed patients and control subjects. Psychosom. Med., 54, 10-21.
36. Joseph-Vanderpool, J. R., Rosenthal, N. E., Chrousos, G. P., Wehr, T. A., Skwerer, R., Kasper, S., & Gold, P. W. (1991). Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder. J. Clin. Endocrinol. Metab., 12, 1382-1387.
37. Kubera, M., Kenis, G., Bosmans, E., Zieba, A., Dudek, D., Nowak, G., & Maes, M. (2000). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: Comparison between the acute state and after remission. Pol. J. Pharmacol., 52, 237-241.
38. Lacosta, S., Merali, Z., & Anisman, H. (1998). Influence of interleukin-1 on exploratory behaviors, plasma ACTH and cortisol, and central biogenic amines in mice. Psychopharmacology, 137, 351-361.
39. LeDoux, J. E. (1995). Emotion: Clues from the brain. Ann. Rev. Psychol., 46, 209-235.
40. Levitan, R. D., Kaplan, A. S., Brown, G. M., Joffe, R. T., Levitt, A. J., Vaccarino, F. J., & Kennedy, S. H. (1997). Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression. Biol. Psychiatry, 41, 366-368.
41. Licinio, J., & Wong, M. L. (1999). The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry, 4, 317-327.
42. Maes, M. (1999). Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol., 461, 25-46.
43. Maes, M. (1995). Evidence for an immune response in major depression: A review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 19, 11-38.
44. Maes, M., Capuron, L., Ravaud, A., Gualde, N., Bosmns, E., Egyed, B., Dantzer, R., & Neveu, P. J. (2001). Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology, 24, 130-140.
45. Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 9, 853-858.
46. Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. A+ect Disord., 34, 301-309.
47. Maes, M., Bosmans, E., Meltzer, H. Y., Scharpe, S., & Suy, E. (1993a). Interleukin-1β: A putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry, 150, 1189-1193.
48. Maes, M., Scharpe, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993b). Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res., 49, 11-27.
49. Maes, M., Lambrechts, J., Bosmans, E., Jacobs, J., Suy, E., Vandervorst, C., DeJonckheere, C., Minner, B., & Raus, J. (1992). Evidence for a systemic immune activation during depression: Results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol. Med., 22, 45-53.
50. Maes, M., Bosmans, E., Suy, E., Vandervorst, C., de Jonckheere, C., Minner, B., & Raus, J. (1991). Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1β and soluble interleukin-2 receptor production. Acta Psychiatry Scand., 84, 379-386.
51. Maier, S. F., & Watkins, L. R. (1998). Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev., 105, 83-107.
52. McEwen, B. S. (1998). Stress, adaptation, and disease. Allostasis and allostatic load. Ann. N.Y. Acad. Sci., 840, 33-44.
53. McGinn, L. K., Asnis, G. M., & Rubinson, E. (1996). Biological and clinical validation of atypical depression. Psychiatry Res., 60, 191-198.
54. McGrath, P. J., Stewart, J. W., Harrison, W. M., Ocepek-Wilekson, K., Rabkin, J. G., Nunes, E. N., Wage, S. G., Tricamo, E., Quitkin, F. M., & Klein, D. F. (1992). Predictive value of symptoms of atypical depression for differential drug treatment outcome. J. Clin. Psychopharmacol., 12, 197-202.
55. Merali, Z., Lacosta, S., & Anisman, H. (1997). Effects of interleukin-1β and mild stress on alterations of central monoamines: A regional microdialysis study. Brain Res., 761, 225-235.
56. Meyers, C. A., & Valentine, A. D. (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56-68.
57. Minami, M., Kuraishi, Y., Yamaguchi, T., Nakai, S., Hirai, Y., & Satoh, M. (1991). Immobilization stress induces interleukin-1b mRNA in rat hypothalamus. Neurosci. Lett., 123, 254-256.
58. Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., Onuki, M., & Mitamura, K. (1999). Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry, 156, 1120.
59. Moldofsky, H. (1995). Sleep and the immune system. Int. J. Immunopharmacol., 17, 649-654.
60. Mullar, N., & Ackenheil, M. (1998). Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog. Neuropsychopharm. Biol. Psychiatry, 22, 1-33.
61. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A., Penna, S., Goodkin, R., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001). Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon α. New Eng. J. Med., 344, 961-966.
62. Nassberger, L., & Traskman-Bendz, L. (1993). Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatry Scand., 88, 48-52.
63. Nemeroff, C. B. (1996). The corticotropin-releasing factor (CRF) hypothsesis of depression: New findings and new directions. Mol. Psychiatry, 1, 336-342.
64. Nguyen, K. T., Deak, T., Will, M. J., Hansen, M. K., Hunsaker, B, N., Fleshner, M., Watkins, L. R., & Maier, S. F. (2000). Timecourse and corticosterone sensitivity of the brain, pituitary, and serum inter-leukin-1β protein response to acute stress. Brain Res., 859, 193-201.
65. Nguyen, K. T., Deak, T., Owens, S. M., Kohno, T., Fleshner, M., Watkins, L. R., & Maier, S. F. (1998). Exposure to acute stress induces brain interleukin-1b protein in the rat. J. Neurosci., 18, 2239-2246.
66. Petrovsky, N., & Harrison, L. C. (1997). Diurnal rhythmicity of human cytokine production. J. Immunol., 158, 5163-5168.
67. Plata-Salaman, C., & Turrin, N. (1999). Cytokine interactions and cytokine balance in the brain: Relevance to neurology and psychiatry. Mol. Psychiatry, 4, 303-306.
68. Plata-Salamán, C. R., Ilyin, S. E., Gayle, D., Flynn, M. C., Turrin, N. P., Bedard, T., Merali, Z., & Anisman, H. (2000). Neither acute nor chronic exposure to a naturalistic (predator) stressor influences the IL-1β system, TNF-α, TGF-β1, and neuropeptide mRNAs, CRH or bombesin content in specific brain regions. Brain Res. Bull., 51, 187-193.
69. Plotkin, S. R., Banks, W. A., Maness, L. M., & Kastin, A. J. (2000). Differential transport of rat and human interleukin-1α across the blood-brain barrier and blood-testis barrier in rats. Brain Res., 881, 57-61.
70. Post, R. M., & Weiss, S. R. B. (1995). The neurobiology of treatment-resistant mood disorders. In F. E. Bloom, & D. J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 1155-1170). New York: Raven Press.
71. Post, R. M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry, 149, 999-1010.
72. Ravindran, A. V., Anisman, H., Merali, Z., Charbonneau, Y., Telner, J., Bialik, R. J., Wiens, A., Ellis, J., & Griffiths, J. (1999). Treatment of primary dysthymia with cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am. J. Psychiatry, 156, 1608-1617.
73. Ravindran, A., Griffiths, J., Merali, Z., & Anisman, H. (1995). Lymphocyte subsets in major depression and dysthymia: Modification by antidepressant treatment. Psychosom. Med., 57, 555-563.
74. Rivest, S., & Rivier, C. (1994). Stress and interleukin-1β-induced activation of c-Fos, Ngfi-B and CRF gene expression in the hypothalamic PVN-comparison between Sprague-Dawley, Fisher-344 and Lewis rats. J. Neuroendocrinol., 6, 101-117.
75. Rothwell, N. J. (1999). Cytokines - Killers in the brain. J. Physiol., 514, 3-17.
76. Rothwell, N. J., & Hopkins, S. J. (1995). Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci., 18, 130-136.
77. Schmidt, E. D., Janszen, A. W. J. W., Wouterlood, F. G., & Tilders, F. J. H. (1995). Interleukin-1 induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. J. Neurosci., 15, 7417-7426.
78. Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., & Kirchner, H. (1995). Cytokine production and serum proteins in depression. Scand. J. Immunol., 41, 534-538.
79. Shanks, N., Windle, R. J., Perks, P. A., Harbuz, M. S., Jessop, D. S., Ingram, C. D., & Lightaan, S. L. (2000). Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc. Natl. Acad. Sci. USA, 97, 5645-5650.
80. Shintani, F., Nakaki, T., Kanba, S., Sato, K., Kato, R., & Asai, M. (1995). Role of interleukin-1 in stress responses. Mol. Neurobiol., 10, 47-71.
81. Sluzewska, A. (1999). Indicators of immune activation in depressed patients. Adv. Exp. Med. Biol., 461, 59-74.
82. Sluzewska, A., Rybakowski, J. K., Laciak, M., Mackiewicz, A., Sobieska, M., & Wiktorowicz, K. (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N.Y. Acad. Sci., 762, 474-476.
83. Smith, R. S. (1991). The macrophage theory of depression. Med. Hypotheses, 35, 298-306.
84. Song, C., Dinan, T., & Leonard, B. E. (1994). Changes in immunoglobulin, complement and acute phase protein levels in depressed patients and normal controls. J. A+ect. Disord., 30, 283-288.
85. Song, C., Merali, Z., & Anisman, H. (1999). Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience, 88, 823-836.
86. Tilders, F. J. H., & Schmidt, E. D. (1998). Interleukin-1-induced plasticity of hypothalamic CRH neurons and long-term stress hyperresponsiveness. Ann. N.Y. Acad. Sci., 840, 65-73.
87. Tilders, F. J. H., Schmidt, E. D., & De Goeij, D. C. E. (1993). Phenotypic plasticity of CRF neurons during stress. Ann. N.Y. Acad. Sci., 697, 39-52.
88. Turnbull, A. V., & Rivier, C. (1996). Cytokine effects on neuroendocrine axes: Influence of nitric oxide and carbon monoxide. In N. J. Rothwell (Ed.), Cytokines in the Nervous System (pp. 93-116). London: R.G. Landes.
89. Turrin, N. P., Gayle, D., Ilyin, S. E., Flynn, M. C., Langhans, W., Schwartz, G. J., & Plata-Salaman, C. R. (2001). Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull., 54, 443-453.
90. Watkins, L. R., Maier, S. F., & Goehler, L. E. (1995). Cytokine-to-brain communication: A review & analysis of alternative mechanisms. Life Sci., 11, 1011-1026.
91. Yirmiya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., Barak, O., Reichenberg, A., Cohen, E., Shavit, Y., & Ovadia, H. (1999). Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv. Exp. Med. Biol., 461, 283-316.
92. Yirmiya, R. (1996). Endotoxin produces a depressive-like episode in rats. Brain Res., 711, 163-174.